The predicated demise of racemic new molecular entities is an exaggeration

被引：60

作者：

Agranat, Israel ^{[1
]}

Wainschtein, Silvya R. ^{[1
]}

Zusman, Enav Z. ^{[2
]}

机构：

[1] Hebrew Univ Jerusalem, Inst Chem, IL-91904 Jerusalem, Israel

[2] Tel Aviv Univ, Dept Life & Med Sci, IL-69978 Tel Aviv, Israel

来源：

关键词：

D O I：

10.1038/nrd3657-c1

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

页码：972 / 973

页数：2

共 11 条

[1] Putting chirality to work: The strategy of chiral switches
Agranat, I
Caner, H
Caldwell, A
[J]. NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (10) : 753 - 768
[2] The strategy of enantiomer patents of drugs
Agranat, Israel
Wainschtein, Silvya R.
[J]. DRUG DISCOVERY TODAY, 2010, 15 (5-6) : 163 - 170
[3] [Anonymous], 2012, DRUG STEREOCHEMISTRY
[4] STEREOCHEMISTRY, A BASIS FOR SOPHISTICATED NONSENSE IN PHARMACOKINETICS AND CLINICAL-PHARMACOLOGY
ARIENS, EJ
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 26 (06) : 663 - 668
[5] Trends in the development of chiral drugs
Caner, H
Groner, E
Levy, L
Agranat, I
[J]. DRUG DISCOVERY TODAY, 2004, 9 (03) : 105 - 110
[6] Ellery T, 2012, PHARM LIFECYCLE MANA, P160
[7] Gal J., 2006, CHIRALITY DRUG RES, P3
[8] Mullard A, 2012, NAT REV DRUG DISCOV, V11, P91, DOI 10.1038/nrd3657
[9] *US FDA, 1992, FDAS POL STAT DEV NE
[10] Zusman E. Z., 2012, DRUG INF J, V46, P497